1. Home
  2. HRMY vs DEI Comparison

HRMY vs DEI Comparison

Compare HRMY & DEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$38.12

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo Douglas Emmett Inc.

DEI

Douglas Emmett Inc.

HOLD

Current Price

$11.68

Market Cap

1.8B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRMY
DEI
Founded
2017
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
2020
2006

Fundamental Metrics

Financial Performance
Metric
HRMY
DEI
Price
$38.12
$11.68
Analyst Decision
Buy
Hold
Analyst Count
9
8
Target Price
$44.11
$12.94
AVG Volume (30 Days)
881.8K
1.8M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
7.06%
EPS Growth
7.97
N/A
EPS
1.84
N/A
Revenue
$868,453,000.00
$1,003,982,000.00
Revenue This Year
$19.75
$1.70
Revenue Next Year
$12.88
$2.35
P/E Ratio
$20.92
N/A
Revenue Growth
21.51
1.77
52 Week Low
$25.52
$9.04
52 Week High
$40.87
$16.94

Technical Indicators

Market Signals
Indicator
HRMY
DEI
Relative Strength Index (RSI) 56.72 46.03
Support Level $34.87 $11.14
Resistance Level $39.24 $12.68
Average True Range (ATR) 1.33 0.39
MACD 0.14 -0.03
Stochastic Oscillator 66.49 40.69

Price Performance

Historical Comparison
HRMY
DEI

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About DEI Douglas Emmett Inc.

Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments: the office segment and multifamily segment, of which Office segment derives maximum revenue.

Share on Social Networks: